v3.26.1
Segment (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting Information [Line Items]    
Number of reporting segments | segment 1  
Revenue:    
Total revenue $ 139,071 $ 114,473
Cost of revenue:    
Intangible asset amortization - cost of revenue 2,707 2,585
Gross profit 101,159 79,508
Operating expenses:    
Total research and development 27,098 17,720
Total selling and marketing 27,156 24,454
Total general and administrative 23,680 33,808
Other income, net (7,328) (4,524)
Income tax provision 1,267 381
Net income 28,707 7,047
Testing revenue    
Revenue:    
Total revenue 135,091 107,309
Cost of revenue:    
Cost of revenue 33,306 28,260
Product revenue    
Revenue:    
Total revenue 3,679 3,580
Cost of revenue:    
Cost of revenue 1,891 1,422
Biopharmaceutical and other revenue    
Revenue:    
Total revenue 301 3,584
Cost of revenue:    
Cost of revenue 8 2,698
Intangible asset amortization - operating expenses    
Operating expenses:    
Intangible asset amortization - operating expenses 579 622
Reportable Segment    
Revenue:    
Total revenue 139,071 114,473
Cost of revenue:    
Intangible asset amortization - cost of revenue 2,707 2,585
Gross profit 101,159 79,508
Operating expenses:    
Total research and development 27,098 17,720
Total selling and marketing 27,156 24,454
Total general and administrative 23,680 33,808
Other income, net (7,328) (4,524)
Income tax provision 1,267 381
Net income 28,707 7,047
Reportable Segment | Research and development:    
Operating expenses:    
Compensation expense 15,547 9,748
Direct expense 4,198 4,141
Other research and development expenses 5,460 1,815
Allocation of facilities and IT expenses 1,893 2,016
Reportable Segment | Selling and marketing:    
Operating expenses:    
Compensation expense 19,972 17,635
Direct expense 1,455 710
Other selling and marketing expenses 4,561 3,853
Allocation of facilities and IT expenses 1,168 2,256
Reportable Segment | General and administrative:    
Operating expenses:    
Compensation expense 16,236 20,173
Other general and administrative expenses 13,471 21,890
Allocation of facilities and IT expenses (6,027) (8,255)
Reportable Segment | Testing revenue    
Revenue:    
Total revenue 135,091 107,309
Cost of revenue:    
Laboratory supplies and reagents expense 12,314 13,067
Sample collection expense 3,288 2,825
Compensation expense 9,804 5,611
Other cost 4,937 3,385
Allocation of facilities and IT expenses 2,963 3,372
Cost of revenue 33,306 28,260
Reportable Segment | Product revenue    
Revenue:    
Total revenue 3,679 3,580
Cost of revenue:    
Product costs 1,401 109
License fees and royalties 313 324
Other cost 174 792
Allocation of facilities and IT expenses 3 197
Cost of revenue 1,891 1,422
Reportable Segment | Biopharmaceutical and other revenue    
Revenue:    
Total revenue 301 3,584
Cost of revenue:    
Compensation expense 0 1,240
Other cost 8 1,044
Allocation of facilities and IT expenses 0 414
Cost of revenue 8 2,698
Reportable Segment | Intangible asset amortization - operating expenses    
Operating expenses:    
Intangible asset amortization - operating expenses $ 579 $ 622